Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01763866




Registration number
NCT01763866
Ethics application status
Date submitted
7/01/2013
Date registered
9/01/2013
Date last updated
8/11/2022

Titles & IDs
Public title
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Scientific title
A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Secondary ID [1] 0 0
2012-001363-70
Secondary ID [2] 0 0
20110115
Universal Trial Number (UTN)
Trial acronym
LAPLACE-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hyperlipidemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Evolocumab
Treatment: Drugs - Ezetimibe
Treatment: Drugs - Placebo to Evolocumab
Treatment: Drugs - Placebo to Ezetimibe
Treatment: Drugs - Atorvastatin
Treatment: Drugs - Rosuvastatin
Treatment: Drugs - Simvastatin

Placebo Comparator: A10 PBO Q2W - Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.

Placebo Comparator: A10 PBO QM - Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.

Active Comparator: A10 EZE (Q2W) - Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.

Active Comparator: A10 EZE (QM) - Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.

Experimental: A10 EvoMab Q2W - Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Experimental: A10 EvoMab QM - Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks

Placebo Comparator: A80 PBO Q2W - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Placebo Comparator: A80 PBO QM - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.

Active Comparator: A80 EZE (Q2W) - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.

Active Comparator: A80 EZE (QM) - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.

Experimental: A80 EvoMab Q2W - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Experimental: A80 EvoMab QM - Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

Placebo Comparator: R5 PBO Q2W - Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Placebo Comparator: R5 PBO QM - Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Experimental: R5 EvoMab Q2W - Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Experimental: R5 EvoMab QM - Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Placebo Comparator: R40 PBO Q2W - Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Placebo Comparator: R40 PBO QM - Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Experimental: R40 EvoMab Q2W - Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Experimental: R40 EvoMab QM - Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Placebo Comparator: S40 PBO Q2W - Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Placebo Comparator: S40 PBO QM - Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Experimental: S40 EvoMab Q2W - Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Experimental: S40 EvoMab QM - Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.


Other interventions: Evolocumab
Administered by subcutaneous injection

Treatment: Drugs: Ezetimibe
Administered orally once a day

Treatment: Drugs: Placebo to Evolocumab
Administered by subcutaneous injection

Treatment: Drugs: Placebo to Ezetimibe
Administered orally once a day

Treatment: Drugs: Atorvastatin
Administered orally once a day

Treatment: Drugs: Rosuvastatin
Administered orally once a day

Treatment: Drugs: Simvastatin
Administered orally once a day
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Primary outcome [2] 0 0
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Timepoint [2] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [1] 0 0
Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12
Timepoint [1] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [2] 0 0
Change From Baseline in LDL-C at Week 12
Timepoint [2] 0 0
Baseline and Week 12
Secondary outcome [3] 0 0
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
Timepoint [3] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [4] 0 0
Percent Change From Baseline in Non-HDL-C at Week 12
Timepoint [4] 0 0
Baseline and Week 12
Secondary outcome [5] 0 0
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Timepoint [5] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [6] 0 0
Percent Change From Baseline in Apolipoprotein B at Week 12
Timepoint [6] 0 0
Baseline and Week 12
Secondary outcome [7] 0 0
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Timepoint [7] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [8] 0 0
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Timepoint [8] 0 0
Baseline and Week 12
Secondary outcome [9] 0 0
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Timepoint [9] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [10] 0 0
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Timepoint [10] 0 0
Baseline and Week 12
Secondary outcome [11] 0 0
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
Timepoint [11] 0 0
Weeks 10 and 12
Secondary outcome [12] 0 0
Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
Timepoint [12] 0 0
Week 12
Secondary outcome [13] 0 0
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Timepoint [13] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [14] 0 0
Percent Change From Baseline in Lipoprotein(a) at Week 12
Timepoint [14] 0 0
Baseline and Week 12
Secondary outcome [15] 0 0
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Timepoint [15] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [16] 0 0
Percent Change From Baseline in Triglycerides at Week 12
Timepoint [16] 0 0
Baseline and Week 12
Secondary outcome [17] 0 0
Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
Timepoint [17] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [18] 0 0
Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12
Timepoint [18] 0 0
Baseline and Week 12
Secondary outcome [19] 0 0
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Timepoint [19] 0 0
Baseline and Weeks 10 and 12
Secondary outcome [20] 0 0
Percent Change From Baseline in HDL-C at Week 12
Timepoint [20] 0 0
Baseline and Week 12

Eligibility
Key inclusion criteria
- Male or female = 18 to = 80 years of age

- Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0
mmol/L)

- Subjects already on a non-intensive statin must have fasting LDL-C at screening = 100
mg/dL (2.6 mmol/L)

- Subjects already on a intensive statin must have fasting LDL-C at screening = 80 mg/dL
(2.1 mmol/L)

- Fasting triglycerides = 400 mg/dL (4.5 mmol/L)
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Statin intolerance

- New York Heart association (NYHA) III or IV heart failure

- Uncontrolled hypertension

- Uncontrolled cardiac arrhythmia

- Type 1 diabetes, poorly controlled type 2 diabetes

- Uncontrolled hypothyroidism or hyperthyroidism

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/01/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/12/2013
Sample size
Target
Accrual to date
Final
2067
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Sydney
Recruitment hospital [2] 0 0
Research Site - Ashford
Recruitment hospital [3] 0 0
Research Site - Fullarton
Recruitment hospital [4] 0 0
Research Site - Fitzroy
Recruitment hospital [5] 0 0
Research Site - Heidelberg Heights
Recruitment hospital [6] 0 0
Research Site - Richmond
Recruitment postcode(s) [1] 0 0
2022 - Sydney
Recruitment postcode(s) [2] 0 0
5035 - Ashford
Recruitment postcode(s) [3] 0 0
5063 - Fullarton
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment postcode(s) [5] 0 0
3081 - Heidelberg Heights
Recruitment postcode(s) [6] 0 0
3121 - Richmond
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
South Dakota
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Belgium
State/province [29] 0 0
Blankenberge
Country [30] 0 0
Belgium
State/province [30] 0 0
Chênée
Country [31] 0 0
Belgium
State/province [31] 0 0
Hasselt
Country [32] 0 0
Belgium
State/province [32] 0 0
Oostende
Country [33] 0 0
Belgium
State/province [33] 0 0
Tremelo
Country [34] 0 0
Belgium
State/province [34] 0 0
Vilvoorde
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Newfoundland and Labrador
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Kladno
Country [41] 0 0
Czechia
State/province [41] 0 0
Litomerice
Country [42] 0 0
Czechia
State/province [42] 0 0
Moravske Budejovice
Country [43] 0 0
Czechia
State/province [43] 0 0
Olomouc
Country [44] 0 0
Czechia
State/province [44] 0 0
Pardubice
Country [45] 0 0
Czechia
State/province [45] 0 0
Praha 2
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha 3
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 4
Country [48] 0 0
Czechia
State/province [48] 0 0
Slany
Country [49] 0 0
Czechia
State/province [49] 0 0
Svitavy
Country [50] 0 0
Czechia
State/province [50] 0 0
Usti nad Orlici
Country [51] 0 0
Denmark
State/province [51] 0 0
Aalborg
Country [52] 0 0
Denmark
State/province [52] 0 0
Ballerup
Country [53] 0 0
Denmark
State/province [53] 0 0
Vejle
Country [54] 0 0
France
State/province [54] 0 0
Brest Cedex 2
Country [55] 0 0
France
State/province [55] 0 0
Caen Cedex 9
Country [56] 0 0
France
State/province [56] 0 0
Dijon
Country [57] 0 0
France
State/province [57] 0 0
Le Creusot
Country [58] 0 0
France
State/province [58] 0 0
Montpellier cedex 05
Country [59] 0 0
France
State/province [59] 0 0
Nantes Cedex 1
Country [60] 0 0
France
State/province [60] 0 0
Paris cedex 12
Country [61] 0 0
France
State/province [61] 0 0
Paris
Country [62] 0 0
France
State/province [62] 0 0
Poitiers
Country [63] 0 0
France
State/province [63] 0 0
Strasbourg
Country [64] 0 0
Germany
State/province [64] 0 0
Bad Krozingen
Country [65] 0 0
Germany
State/province [65] 0 0
Berlin (Hellersdorf)
Country [66] 0 0
Germany
State/province [66] 0 0
Berlin
Country [67] 0 0
Germany
State/province [67] 0 0
Freiburg
Country [68] 0 0
Germany
State/province [68] 0 0
Heidelberg
Country [69] 0 0
Germany
State/province [69] 0 0
Homburg
Country [70] 0 0
Germany
State/province [70] 0 0
Leipzig
Country [71] 0 0
Germany
State/province [71] 0 0
Magdeburg
Country [72] 0 0
Germany
State/province [72] 0 0
Messkirch
Country [73] 0 0
Germany
State/province [73] 0 0
Witten
Country [74] 0 0
Hong Kong
State/province [74] 0 0
Hong Kong
Country [75] 0 0
Hong Kong
State/province [75] 0 0
New Territories
Country [76] 0 0
Hungary
State/province [76] 0 0
Baja
Country [77] 0 0
Hungary
State/province [77] 0 0
Berettyoujfalu
Country [78] 0 0
Hungary
State/province [78] 0 0
Dunaujvaros
Country [79] 0 0
Hungary
State/province [79] 0 0
Eger
Country [80] 0 0
Hungary
State/province [80] 0 0
Gyongyos
Country [81] 0 0
Hungary
State/province [81] 0 0
Hodmezovasarhely
Country [82] 0 0
Hungary
State/province [82] 0 0
Jaszbereny
Country [83] 0 0
Hungary
State/province [83] 0 0
Komarom
Country [84] 0 0
Hungary
State/province [84] 0 0
Marcali
Country [85] 0 0
Hungary
State/province [85] 0 0
Mosonmagyarovar
Country [86] 0 0
Hungary
State/province [86] 0 0
Pecs
Country [87] 0 0
Italy
State/province [87] 0 0
Bologna
Country [88] 0 0
Italy
State/province [88] 0 0
Cagliari
Country [89] 0 0
Italy
State/province [89] 0 0
Chieti
Country [90] 0 0
Italy
State/province [90] 0 0
Ferrara
Country [91] 0 0
Italy
State/province [91] 0 0
Milano
Country [92] 0 0
Italy
State/province [92] 0 0
Napoli
Country [93] 0 0
Italy
State/province [93] 0 0
Padova
Country [94] 0 0
Italy
State/province [94] 0 0
Perugia
Country [95] 0 0
Italy
State/province [95] 0 0
Pisa
Country [96] 0 0
Italy
State/province [96] 0 0
Trieste
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Suwon-si
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Suwon
Country [100] 0 0
Mexico
State/province [100] 0 0
Distrito Federal
Country [101] 0 0
Mexico
State/province [101] 0 0
Guanajuato
Country [102] 0 0
Mexico
State/province [102] 0 0
Jalisco
Country [103] 0 0
Mexico
State/province [103] 0 0
Nuevo León
Country [104] 0 0
Mexico
State/province [104] 0 0
San Luis PotosÃ-
Country [105] 0 0
Mexico
State/province [105] 0 0
Tamaulipas
Country [106] 0 0
Mexico
State/province [106] 0 0
Durango
Country [107] 0 0
Netherlands
State/province [107] 0 0
Amsterdam
Country [108] 0 0
Netherlands
State/province [108] 0 0
Den Helder
Country [109] 0 0
Netherlands
State/province [109] 0 0
Groningen
Country [110] 0 0
Netherlands
State/province [110] 0 0
Hoogeveen
Country [111] 0 0
Netherlands
State/province [111] 0 0
Nieuwegein
Country [112] 0 0
Netherlands
State/province [112] 0 0
Nijmegen
Country [113] 0 0
Netherlands
State/province [113] 0 0
Rotterdam
Country [114] 0 0
Netherlands
State/province [114] 0 0
Waalwijk
Country [115] 0 0
Netherlands
State/province [115] 0 0
Zwijndrecht
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Barnaul
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Kemerovo
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Moscow
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Novosibirsk
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Saint Petersburg
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Saint-Petersburg
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Saratov
Country [123] 0 0
South Africa
State/province [123] 0 0
Gauteng
Country [124] 0 0
South Africa
State/province [124] 0 0
Western Cape
Country [125] 0 0
South Africa
State/province [125] 0 0
Bloemfontein
Country [126] 0 0
South Africa
State/province [126] 0 0
Cape Town
Country [127] 0 0
Spain
State/province [127] 0 0
AndalucÃ-a
Country [128] 0 0
Spain
State/province [128] 0 0
Cataluña
Country [129] 0 0
Spain
State/province [129] 0 0
Comunidad Valenciana
Country [130] 0 0
Spain
State/province [130] 0 0
Madrid
Country [131] 0 0
Sweden
State/province [131] 0 0
Göteborg
Country [132] 0 0
Sweden
State/province [132] 0 0
Lund
Country [133] 0 0
Sweden
State/province [133] 0 0
Stockholm
Country [134] 0 0
Sweden
State/province [134] 0 0
Uddevalla
Country [135] 0 0
Sweden
State/province [135] 0 0
Ã-rebro
Country [136] 0 0
Switzerland
State/province [136] 0 0
Bellinzona
Country [137] 0 0
Switzerland
State/province [137] 0 0
Geneva 14
Country [138] 0 0
Switzerland
State/province [138] 0 0
Lausanne
Country [139] 0 0
Switzerland
State/province [139] 0 0
Muensterlingen
Country [140] 0 0
Switzerland
State/province [140] 0 0
St. Gallen
Country [141] 0 0
Switzerland
State/province [141] 0 0
Zurich
Country [142] 0 0
Taiwan
State/province [142] 0 0
Kaohsiung
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taipei
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Birmingham
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Blackpool
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Cardiff
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Chesterfield
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Chorley
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Doncaster
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Glasgow
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Harrow
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Liverpool
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Manchester
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Reading
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Scunthorpe
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Wakefield
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Whitby

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered
subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin,
compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol
(LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01763866
Trial related presentations / publications
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.
Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252. Epub 2014 Jan 30.
Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16.
Koren MJ, Jones PH, Robinson JG, Sullivan D, Cho L, Hucko T, Lopez JAG, Fleishman AN, Somaratne R, Stroes E. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiol Ther. 2020 Dec;9(2):447-465. doi: 10.1007/s40119-020-00181-8. Epub 2020 Jun 20.
Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7.
Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7.
Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932.
Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21.
Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1.
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2.
Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.
May HT, Muhlestein JB, Ma Y, Lopez JAG, Coll B, Nelson J. Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiol Ther. 2019 Jun;8(1):91-102. doi: 10.1007/s40119-019-0133-6. Epub 2019 Mar 9.
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01763866